A RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, PHASE 1A/1B MULTI-CENTRE STUDY IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF GSK4771261

Registry ID

221362

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Start date

2026-03-09

Last update

2025-03-19

Conditions

• AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Related clinical trials

• A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF LIXIVAPTAN IN PARTICIPANTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE CONSISTING OF A 1-YEAR DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE AND A 1-YEAR OPEN LABEL PHASE: THE ACTION STUDY
• MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TWO STAGE STUDY TO CHARACTERIZE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GZ/SAR402671 IN PATIENTS AT RISK OF RAPIDLY PROGRESSIVE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD).
• A PILOT STUDY OF CYSTIC VOLUME REDUCTION BY FOAM SCLEROTHERAPY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

View on source registry